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Abstract: 
Palmitoylation is the post-translational, covalent and reversible conjugation of a 16C 
saturated fatty acid to cysteine residues of proteins. The sodium calcium exchanger 
NCX1 is palmitoylated at a single cysteine residue in its large regulatory intracellular 
loop. Inactivation, mediated by the NCX1 inhibitory region XIP, is drastically impaired 
in unpalmitoylatable NCX1. The ability of XIP to bind and inactivate NCX1 is largely 
determined by NCX1 palmitoylation, which induces local conformational changes in 
the NCX1 intracellular loop to enable XIP to engage its binding site. Consequently, 
NCX1 palmitoylation regulates intracellular calcium by changing NCX1 sensitivity to 
inactivation. NCX1 palmitoylation is a dynamic phenomenon which is catalyzed by the 
palmitoyl acyl transferase zDHHC5 and reversed by the thioesterase APT1, with the 
switch between palmitoylated and depalmitoylated states, which has profound effects 
on NCX1 lipid interactions, influenced by NCX1 conformational poise. Herein we 
review the molecular and cellular consequences of NCX1 palmitoylation and its 
physiological relevance and highlight the importance of palmitoylation for NCX1 
activity. We discuss the cellular control of protein palmitoylation and depalmitoylation, 
the relationship between lipid microdomains and lipidated and phospholipid binding 
proteins, and highlight the important unanswered questions in this emerging field. 
  
1. Introduction 
Developing interest in palmitoylation and its physiological consequences in different 
tissues over the last decade has enabled palmitoylation to gain increasing popularity 
and put a spotlight on this unique post-translational modification. Simply put, 
palmitoylation is enzymatically controlled phenomenon involving the dynamic 
attachment of palmitic acid to a target protein via a thioester bond. This unique 
biochemical modification in protein structure to date, has been reported with a 
regulatory role in several cellular and physiological processes in various tissues [1-3]. 
Despite the rich background regarding the role of palmitoylation in the nervous system 
[3], how palmitoylation contributes to cellular events in the cardiac tissue; such as 
calcium homeostasis and cardiac contractility, is poorly understood.  
Various ion channels/transporters and signalling molecules; which work in harmony as 
a team, lie at “the heart” of cardiac tissue. How this complex team functions to maintain 
cellular calcium fluxes in balance to support healthy cardiac function is vital question 
to be addressed. Among hundreds of proteins in the cardiac system, cardiac Na+/Ca2+ 
Exchanger (NCX1) is established as a major player in calcium homeostasis and 
cardiac contractility. NCX1 mediates ~30% of cytosolic calcium removal in ventricles 
in large mammals [4]. NCX1 also acts as a part of rhythmic generator of action 
potential, the calcium clock, in the sinoatrial node (SAN) [5]. Inappropriate NCX1 
behaviour is implicated in various cardiac pathologies with severe consequences [6-
9]. 
NCX1 is 10 transmembrane (TM) domain protein with a large intracellular loop 
between TM5 and TM6. This intracellular loop is a key regulator of NCX1 function and 
is composed of Exchanger Inhibitory Peptide (XIP), Calcium Binding Domains (CBDs; 
CBD1 and CBD2) and the palmitoylation site (Figure 1) [10-16]. These regions promote 
different physiological states of the exchanger; XIP inhibits while calcium binding to 
CBDs activates the transporter [10, 11, 17-19]. Apart from the allosteric regulation of 
activation-inactivation states of NCX1 and the auto-regulation by XIP domain, 
palmitoylation is the first post-translational modification to be identified as a direct 
regulatory mechanism in NCX1 physiology [13-16, 20]. Although the discovery of 
NCX1 palmitoylation and its role in the exchanger function are relatively new to the 
field, the initial findings are promising for palmitoylation to be a powerful tool to tune 
NCX1 physiology. Herein we summarize physiological, molecular and cellular 
consequences of NCX1 palmitoylation updated with recent findings.   
 
2. Brief look up: What is currently known about NCX1 palmitoylation and its 
physiological consequences? 
NCX1 possesses multiple cysteine residues in its structure but exclusively only one 
palmitoylatable cysteine was detected at position 739 in the large intracellular loop of 
the exchanger (Figure 1) [13]. Abolishing NCX1 palmitoylation by introducing a single 
mutation at this site from cysteine to alanine (C739A) causes NCX1 to be unable to 
inactivate properly. Two separate experimental approaches using patch clamp in the 
whole cell configuration showed that a lack of palmitoylation disrupts the inactivation 
pattern of the exchanger. Chelating intracellular calcium with EGTA leads to the loss 
of calcium binding to the NCX1 CBDs. This intervention completely inhibited NCX1 
current in the cells expressing wild type (WT) NCX1, but under the same conditions a 
significant portion of NCX1 current persisted in cells expressing unpalmitoylatable 
(C739A) NCX1. Similarly, the absence of intracellular ATP in the patch clamp 
experiments leads to depletion of PIP2 and release of the endogenous XIP domain to 
inactivate NCX1. PIP2 depletion caused 90% inhibition of wild type (palmitoylatable) 
NCX1 current but only inhibited 30% of the current when NCX1 is unpalmitoylatable 
[13]. So, timely and efficient inactivation of NCX1 requires palmitoylation of cysteine 
739. 
The extent of studies to understand the molecular basis of NCX1 palmitoylation 
uncovered an ɑ helix structure adjacent to palmitoylated cysteine (C739) characterized 
with a large hydrophobic face and a small hydrophilic part (only 4 residues of the helical 
structure; D741, H745, T748 and K752) to control palmitoylation status of the 
exchanger (Figure 1) [15]. Deleting the entire amphipathic structure accommodated 
between 740 and 756 residues or manipulating either hydrophobic or hydrophilic face 
of the helix by mutagenesis drastically eliminated or diminished NCX1 palmitoylation 
(but did not affect the trafficking of NCX1) [15]. Precisely how this structural element 
governs NCX1 palmitoylation still remains unclear. It is likely recognised by the cellular 
palmitoylation machinery.       
         
3. Fresh from the oven: Recent advances on molecular and cellular importance 
of NCX1 palmitoylation 
3.1. Palmitoylation induces conformational changes in the intracellular loop of NCX1 
The existence of an NCX1 dimer in plasma membrane is well-established [21]. The 
functional importance of NCX1 dimerisation is currently uncertain, but restructuring of 
the dimer appears to have important consequences for NCX1 regulation. Calcium 
dependent structural re-arrangements within the large intracellular loop of the 
exchanger were probed in oocyte membrane sheets using FRET sensors generated 
by insertion of either YFP or CFP to full length NCX1 at position 266, immediately after 
the XIP domain in the exchanger’s large regulatory intracellular loop [12]. Binding of 
calcium ions to CBDs, which activates NCX1, promotes conformational changes in 
NCX1 dimers and reduces the distance between NCX1-NCX1 FRET pairs. In a recent 
investigation we probed the impact of palmitoylaton on the NCX1-NCX1 dimer using 
FRET measurements in live cells. We found that enhancing palmitoylation of NCX1 by 
supplementing with palmitic acid (PA) increased NCX1-NCX1 FRET, while reducing 
NCX1 palmitoylation with the palmitoylation inhibitor 2-bromopalmitate (2-BP) or 
complete loss of NCX1 palmitoylation by mutating the palmitoylated cysteine to alanine 
(C739A) reduced NCX1-NCX1 FRET [22]. This data suggest that palmitoylation either 
(1) changes the ability of NCX1 to dimerize or (2) triggers a local conformational 
changes in the existing NCX1 dimer. With the help of cross-linking approach using 
bismaleimidohexane (BMH), the monomer/dimer ratio between palmitoylatable and 
unpalmitoylatable NCX1 was found to be identical [22]. It is now clear that 
palmitoylation restructures the large intracellular loop of the exchanger. 
A note of caution should be sounded on the specificity of the palmitoylation inhibitor 2-
BP, used in these studies. Something of a ‘workhorse’ reagent for the palmitoylation 
field, the mixed pharmacology of 2-BP is extensively documented, but frequently 
ignored [23]. Cell convert 2-BP to its CoA ester, which irreversibly inhibits zDHHC-
PATs by modifying their active site [24]. However, 2-BP was established to inhibit 
mitochondrial fatty acid oxidation nearly 50 years ago [25], and recent studies using 2-
BP analogues have identified numerous cellular targets other than zDHHC-PATs for 
this very promiscuous reagent [26, 27], including the depalmitoylating enzymes 
themselves [28]. Unfortunately, the field is yet to identify a zDHHC-PAT inhibitor with 
a more reliable pharmacology. Given the concerns about its specificity, we suggest 2-
BP should only be employed alongside genetic approaches (cysteine to alanine 
mutations, zDHHC-PAT silencing) to probe the functional consequences of protein 
palmitoylation. 
 
3.1.1. What does NCX1-NCX1 FRET tell us about physiology and ion transport? 
From the point of view of NCX activity, it is important to consider what the high FRET 
and low FRET forms of NCX1 actually represent, and what regulatory mechanisms 
might be signposted for future investigation? The FRET experiments by John and 
colleagues that concentrated on calcium dependent re-structuring of NCX1 dimers 
reported increased FRET signals between existing NCX1-NCX1 dimers following 
NCX1 activation by Ca2+ binding to CBDs [12]. Mutations within CBD1 abolished Ca2+ 
dependent structural changes within the intracellular loop of the exchanger detected 
using FRET. On the other hand, mutation of CBD2 did not affect NCX1-NCX1 FRET 
behaviour but did impair calcium regulation. This indicates that the Ca2+-induced dimer 
movement between NCX1 pairs measured by NCX1-NCX1 FRET occurs mainly as a 
result of Ca2+ binding to CBD1. One might question the ability of FRET sensors 
positioned at 266 to detect CBD2-driven structural rearrangements. Clearly, CBD1 is 
situated nearer the sensors, which may enhance their ability to detect any re-
structuring of this region. However, the fact that palmitoylation-dependent changes in 
NCX1-NCX1 FRET can be detected even though the palmitoylation site is further from 
the FRET sensors than CBD2 suggests that the sensors are positioned appropriately 
to detect restructuring throughout the NCX1 intracellular loop.  
As for our understanding of what the impact of palmitoylation on NCX1-NCX1 FRET 
means for NCX1 itself, several intriguing possibilities exist. The fact that the 
palmitoylation-dependent change in NCX1-NCX1 FRET requires intact lipid rafts (see 
section 3.2) clearly implicates changes in phospholipid interactions with the exchanger 
driven by palmitoylation. We need to understand the identities and regulatory role of 
these phospholipids. However, another significant effect of palmitoylation on NCX1 is 
to enhance its affinity for the inhibitory XIP domain (see section 3.5). It may be that we 
can marry these observations of enhanced NCX1-NCX1 FRET and enhanced NCX1 
inactivation if inactivation by XIP occurs “in trans” between NCX1 dimers. In other 
words, perhaps the FRET change induced by NCX1 palmitoylation reports the 
changes in distance between the XIP domain in one protomer and its binding site on 
the second. 
 
3.2. Palmitoylation of NCX1 modifies its affinity for and the behaviour of lipid 
microdomains 
The physical mechanisms underlying partitioning of proteins into lipid microdomains 
are the subject of ongoing investigations. Indeed, it is likely that numerous 
mechanisms, including cholesterol binding motifs, transmembrane domain physical 
properties and tertiary structure, and the presence of lipid modifications control 
microdomain affinity [29-32]. Investigations in Giant Plasma Membrane Vesicle 
(GPMV); a model system that is cell-detached structures (Figure 2A) [33-36], have 
elucidated an important role for palmitoylation to enhance the affinity of proteins for the 
raft (ordered) phase of isolated membranes which is rich in saturated phospholipids, 
cholesterol, glycolipids and sphingolipids [31, 37]. For example, the transmembrane 
linker for activation of T cells (LAT) clustering in the lipid rafts is markedly dependent 
on its palmitoylation status at two juxtamembrane cysteines [31].  
Since a typical GPMV sustains the lipid and protein composition of the native 
membrane, it is an ideal and sophisticated model to look into protein distribution 
through lipid microdomains. We induced phase separation in GPMVs to unravel how 
palmitoylation impacts the interaction of the exchanger with lipid microdomains, and 
found that loss of palmitoylation remarkably prompts the localization of NCX1 almost 
entirely within the non-raft (disordered) phase enriched with phospholipids 
incorporating unsaturated fatty acids (Figure 2) [22]. Curiously, although palmitoylated 
NCX1 showed a significantly greater overlap with lipid raft markers than non-
palmitoylated NCX1 (Figure 2D), the ability of GPMVs to separate into raft and non-
raft phases was impaired by the presence of palmitoylated NCX1. The overlap of raft 
and non-raft markers was significantly greater when NCX1 was palmitoylated than 
when it wasn’t (Figure 2C). This implies a direct effect of palmitoylated NCX1 on lipid 
behaviour within GPMVs, a phenomenon for which other precedents are emerging. 
For example, the integral membrane protein PMP22 has recently been found to 
enhance phase separation of GPMVs and alter the circumference of the GPMVs in 
which it resides, confirming that multi-pass integral membrane proteins can alter the 
biophysical properties of membranes in which they reside [32]. Indeed NCX1 and 
PMP22 represent the first examples of multi-pass integral membrane proteins to show 
a significant affinity for the ordered phase of GPMVs – albeit via very different 
mechanisms. 
So how does palmitoylated NCX1 exert an influence on GPMV phase separation? 
Since the XIP domain of NCX1 binds PIP2, it is tempting to speculate that the 
recruitment of this lipid species (which is usually confined to the non-raft phase in 
GPMVs) conflicts with an enhanced affinity of palmitoylated NCX1 for raft phase lipids, 
impairing phase separation and effectively lowering the temperature at which phase 
separation can be achieved. This is similar to molecular dynamics simulations of the 
partitioning of palmitoylated and farnesylated H-Ras, in which the saturated palmitate 
attracts H-Ras to the lipid ordered phase, but the unsaturated farnesyl attracts it to the 
disordered phase. As a result, H-ras is thought to cluster at order / disorder boundaries 
[38]. In our experiments, the ability of NCX1 to bind the unsaturated lipid PIP2 may 
generate the same outcome in GPMVs. We therefore suggest a similar impact on the 
partitioning of a protein between ordered and disordered phases for a multi-pass 
integral membrane protein (via PIP2 binding and dynamic palmitoylation) as has been 
established for peripheral membrane proteins (via palmitoylation and farnesylation). 
A similar phenomenon has also recently been postulated for the dually palmitoylated 
PIP2 binding protein CD44. Palmitoylation recruits CD44 into the raft phase, while PIP2 
can extract singly but not doubly palmitoylated CD44 from rafts [39]. Additional 
complexity in this system is generated by the unequal contributions of the two 
palmitoylation sites to CD44 raft affinity. The CD44 cytosolic palmitoylation site 
presents its palmitoyl chain perpendicular to the membrane normal, which allows it to 
insert parallel to the phospholipid tails. In contrast, the palmitoyl chains attached to the 
CD44 integral membrane palmitoylation site are forced to adopt an unfavourable angle 
relative to the bilayer. In other words, simply being palmitoylated isn’t the only thing to 
consider with respect to lipid raft localization; the distance of a palmitoylation site from 
a transmembrane domain will also impact raft affinity of an integral membrane protein. 
Why is this so important for the cell? Many other palmitoylated peripheral and integral 
membrane proteins also bind PIP2. Ultimately then, palmitoylation of a lipid anchored 
or lipid binding protein may remodel the local membrane environment and influence 
binding of regulatory lipid species as well as modifying the structure and function of 
the target protein itself, with important implications for cell physiology. 
Supporting the data gathered in GPMV experiments, remodelling the plasma 
membrane in intact cells with methyl-β-cyclodextrin (MβCD); to deplete cholesterol 
acutely, or SDS; to promote increased raft formation, modifies NCX1-NCX1 FRET only 
when it is palmitoylatable. Much like 2-BP discussed above, the use of MβCD to 
deplete cholesterol and destroy membrane rafts is frequently criticised as a blunt tool 
with significant potential for off-target effects [40]. This reagent must be used cautiously 
as part of an integrated repertoire of approaches to understand membrane raft roles 
and behaviours. Cholesterol depletion in the intact cells expressing WT-NCX1 reduced 
FRET between NCX1 pairs, but NCX1-NCX1 FRET was increased when raft formation 
was enhanced by SDS treatment. Neither MβCD nor SDS treatment affected FRET 
behaviour of unpalmitoylatable (C739A) NCX1 [22]. So, when NCX1 cannot be 
palmitoylated, it cannot recognize and interact with the raft phase. These findings 
suggest a new notion that raft formation or the presence of particular phospholipid 
species might be a factor facilitating or even required for palmitoylation-induced 
restructuring of the NCX1 intracellular loop. This may explain why manipulating lipid 
composition of plasma membrane in intact cells with MβCD and SDS affected NCX1-
NCX1 FRET only in palmitoylatable NCX1; more rafts= high FRET and less rafts= low 
FRET. To conclude, palmitoylation of NCX1 is a key process for appropriate interaction 
with lipids. 
 
3.3. Allosteric regulation and NCX1 palmitoylation 
Ion transport by NCX1 is an entirely thermodynamically driven event, but it can be 
facilitated or inhibited by allosteric regulation. This concept of allosteric regulation of 
NCX1 was originally identified over 3 decades ago by Kimura and colleagues [41]. 
NCX1 is allosterically activated by increased cytosolic calcium binding to the CBDs, 
which increases the rate of ion exchange across the membrane. Elevated cytosolic 
sodium allosterically inactivates NCX1 in a process usually referred to as sodium-
dependent inactivation [42]. We found that FRET between NCX1 pairs differs in 
response to different extracellular buffers; Tyrode’s, Na+ free- and Ca2+ free- buffer. 
Compared to recordings made in Tyrode’s, exposing cells expressing WT-NCX1 to 
Na+ containing, Ca2+ free extracellular solutions enhanced NCX1-NCX1 FRET, while 
Ca2+ containing, Na+ free buffers reduced the FRET signal between NCX1 pairs. Of 
course, allosteric regulation has long been known to put NCX1 through conformational 
changes to adapt to distinct ionic conditions. However, in FRET experiments, 
unpalmitoylatable NCX1 responded to the changes in extracellular environment 
differently from WT-NCX1: the FRET signal of unpalmitoylatable exchanger was 
enhanced in Ca2+ containing, Na+ free conditions, but there was no change in FRET 
signals in Na+ containing, Ca2+ free extracellular solutions. We also noted a striking 
increase in NCX1 palmitoylation in the cells incubated in Ca2+ free buffer and a 
decrease in Na+ free buffer, suggesting that a cycle between palmitoylated and 
depalmitoylated state of NCX1 is promoted by distinct ion-bound structures [22].  
Not only does this imply that palmitoylation and depalmitoylation of NCX1 occurs 
dynamically in the cell (see section 3.4), but it also suggests that the palmitoylation 
machinery can distinguish between the structures adopted by NCX1 when it is 
allosterically regulated. The enhanced FRET signal of unpalmitoylatable NCX1 in Ca2+ 
containing, Na+ free conditions may represent the previously-established Ca2+-
dependent FRET changes induced by Ca2+ binding to CBD1 [12]. However, this 
modest increase in FRET is dwarfed by a very substantial decrease in FRET under 
the same conditions when NCX1 can be palmitoylated. Meanwhile the enhanced 
NCX1 palmitoylation and FRET observed in Na+ containing, Ca2+ free conditions 
suggests a positive feedback loop in which sodium binding to its allosteric regulatory 
site (already established to promote NCX1 inactivation) enhances NCX1 
palmitoylation, further sensitizing it to inactivation by XIP. Hence palmitoylation 
appears to be an important feature of the allosteric regulatory mechanisms for NCX1. 
 
3.4. Palmitoylation of NCX1 is catalysed dynamically at cell surface by zDHHC5 and 
reversed by APT1 
The palmitoylation/depalmitoylation cycle is an enzymatically controlled process. 
Catalysis of protein palmitoylation involves protein-acyltransferases (PATs), a large 
family with twenty three isoforms. These integral membrane proteins typically have 4 
transmembrane domains, with the catalytic site within a unique cysteine rich, zinc 
finger containing motif: Asp-His-His-Cys (zDHHC) [24, 43]. Most zDHHC-PATs are 
found at a single (sometimes two) location(s) within the secretory pathway, with the 
Golgi apparatus widely recognised as the cellular palmitoylation ‘hub’ [44-47], and 
relatively few zDHHC-PATs responsible for dynamic palmitoylation of proteins residing 
at the cell surface. Substrate recognition rules and upstream control of zDHHC-PAT 
activity is an emerging area of research. Some zDHHC-PATs display high activity but 
relatively low substrate affinity and specificity [48, 49]. Others, among them zDHHCs 
5, 13 and 17, form stable interactions with their substrates, making them amenable to 
affinity purification techniques [49, 50]. Regulation of cardiac excitability and 
contractility by dynamic palmitoylation of ion transporters has been discussed in detail 
by others [51]. Briefly, zDHHC-PATs control cardiomyocyte excitability by regulating 
the voltage gated sodium channel SCN5a [52], active transport by the Na/K ATPase 
via its accessory protein phospholemman [49, 53, 54], action potential duration by the 
potassium channel Kv4.3 via its accessory protein KChiP2 [55, 56], calcium influx via 
the beta subunit of the L-type Ca2+ channel [57, 58], as well as contractility via 
phospholamban [59] and NCX1. Until very recently, of the cell surface ion transport 
regulators it was only phospholemman that had been ‘paired’ with a palmitoylating 
enzyme, the cell surface zDHHC-PAT zDHHC5 [49, 50, 60]. 
Compared to the large family of PATs identified in yeast [61, 62] and mammals [63-
68], our knowledge about depalmitolating enzymes is limited with the discovery of acyl-
protein thioesterases (APTs; APT1 and APT2) [69-72], lysosomal palmitoyl-protein 
thioesterases (PPTs; PPT1 and PPT2) [73-75] and recently identified FASN, PNPLA6, 
ABHD6, ABHD16A, ABHD17A/B/C [76]. 
 
3.4.1. The NCX1 depalmitoylating enzyme, APT1 
Detailed mutagenesis scanning on NCX1 structure has brought a deep understanding 
of structural elements involving in palmitoylation of NCX1. As aforementioned, the ɑ-
helix structure that sits between residues 740 and 756 is a key structural element for 
NCX1 palmitoylation. Hypothesising that this helical structure interacts with the 
enzyme(s) involved in the NCX1 palmitoylation/depalmitoylation process, the heart 
and brain interactomes of a biotin-tagged peptide which corresponds to this helix were 
idenitfied using LC-MS/MS. Notably, the only palmitoylation/depalmitoylation 
processes related protein which was pulled out by this peptide was APT1. Further 
experimental approaches using pharmacological tools targeting APT1 and APT2 
confirmed that APT1 but not APT2 reverses NCX1 palmitoylation [22]. The relatively 
non-specific thioesterase inhibitor Palmostatin B and the APT1-specific inhibitor ML-
348 both increased steady state NCX1 palmitoylation when applied to HEK cells and 
adult ventricular myocytes. In contrast, the APT2-specific inhibitor ML-349 did not alter 
NCX1 palmitoylation in either cell type.  
The original investigations of the depalmitoylating activity of APT1 (also known as 
LYPLA1) concluded that this enzyme was cytosolic [70], a finding that was replicated 
in many follow-up studies. In contrast, a recent investigation suggested that the 
majority of APT1 is localised in mitochondria [77]. In live cells, mitochondrially-targeted 
fluorescence-based activity probes engineered to detect cysteine deacylation activity 
demonstrated the presence of active depalmitoylating enzymes in mitochondria. 
Subsequent siRNA and pharmacological screens suggested that a substantial fraction 
of the mitochondrial deacylation activity detected by these probes was due to the 
presence of APT1 in mitochondria, while ATP2 was found in the cytosol and at the 
Golgi apparatus. Myc-tagged APT1 localised to mitochondria while fluorescent protein 
APT1 fusions did not, and endogenous APT1 copurified with mitochondrial markers in 
fractionation experiments (although in the same experiments a small fraction of 
endogenous APT1 was found outside mitochondria) [77]. It is difficult to reconcile these 
observations with the very many papers that rigorously demonstrate that APT1 is 
cytosolic in eukaryotes from yeast to mammals [70-72, 78-81]. The ability of APT1 to 
depalmitoylate non-mitochondrial targets such as heterotrimeric and small G proteins 
is well accepted [82]. Indeed, a recent quantitative palmitoyl-proteomics screen of 
APT1 knockout endothelial cells identified 52 candidate APT1 substrates, none of 
which are annotated as mitochondrial proteins [83]. So, this enzyme appears to live a 
dual life. A small (but from a palmitoylation perspective the functionally significant) 
population depalmitoylates non-mitochondrial proteins in the Golgi apparatus and at 
the plasma membrane – including NCX1. A second pool resides in mitochondria. The 
identity of the mitochondrial APT1 substrates remains elusive, raising the possibility 
that mitochondrial-localised APT1 either has no unique substrates, or performs an 
enzymatic function distinct from depalmitoylation (for example, hydrolysis of long chain 
mono-acyl glycerol esters [84]). To date, only the recently-identified depalmitoylating 
enzyme ABHD10 has been established to depalmitoylate a mitochondrial substrate – 
the redox sensitive protein peroxiredoxin 5 [85]. 
 
3.4.2. An NCX1 palmitoylating enzyme, zDHHC5 
Surprisingly, our proteomics experiments identified no zDHHC-PATs in the affinity 
purification experiments using the palmitoylation-directing NCX1 ɑ-helix. This might be 
due to the limitation in the specificity/detection capability of LC-MS/MS. In our 
extensive experience detecting integral membrane proteins using mass spectrometry 
[50, 86], zDHHC-PATs are only rarely observed, suggesting they are relatively low 
copy number proteins. In a separate experiment we evaluated a relationship between 
NCX1 and zDHHC5, a cell-surface located zDHHC-PAT [87] which recognizes its 
substrates via its extended C tail [49]. Using a peptide library based on the zDHHC5 
C-tail, we found zDHHC5 interacts with NCX1 [22]. In experiments in zDHHC5-KO 
cells, NCX1 was still palmitoylated, albeit to a lesser extent than in wild type HEK cells. 
Re-introducing zDHHC5 into zDHHC5-KO cells significantly increased NCX1 
palmitoylation. This suggests that not only zDHHC5 but also other zDHHC-PATs 
catalyse NCX1 palmitoylation. FRET between NCX1 pairs in zDHHC5-KO cells was 
not altered significantly by Ca2+ free conditions as opposed to those measured in wild 
type HEK cells [22], suggesting that the changes in NCX1 palmitoylation associated 
with allosteric regulation require the presence of zDHHC5. These findings are 
important to understand the nature of palmitoylation/depalmitoylation of NCX1. On the 
other hand, the substantial residual palmitoylation of NCX1 in zDHHC5-KO cells 
means that more experiments are needed to understand the full repertoire of zDHHC-
PATs that are capable of palmitoylating NCX1. 
Interestingly, the region of the zDHHC5 C tail that interacts with NCX1 is the same 
region that we recently established to interact with the Na pump / PLM complex via the 
pump’s third intracellular loop. Functional and physical interactions between the Na 
pump and NCX1 are well established [88-91]; whether such interactions are relevant 
to zDHHC5 regulation of either transporter remains to be established. The region of 
zDHHC5 that interacts with the Na pump and NCX1 in cardiac muscle has also been 
implicated in adaptor protein interactions and zDHHC5 substrate recruitment in other 
tissues [92, 93]. Hence zDHHC5 selection of substrates may depend on the tissue-
specific presence or absence of adapters facilitating substrate engagement. Such a 
phenomenon is not unique to zDHHC5, as zDHHC9 palmitoylation of H-ras also relies 
on the presence of an adaptor protein [68]. However, the majority of zDHHC-PATs are 
thought to either engage directly with their substrates [24, 94], or to utilise recognition 
motifs integral to their N and / or C termini (for example ankyrin repeats [95]). 
Serendipitously, this unique complexity associated with substrate recruitment by 
zDHHC5 offers the opportunity for tissue-specific or substrate-specific targeting, once 
the molecular contact points between zDHHC5 and its substrates have been identified 
[96]. 
The mechanisms underlying regulation of zDHHC5 substrate palmitoylation have been 
the subject of considerable interest recently. Palmitoylation of the zDHHC5 C tail by 
zDHHC20 increases Na pump recruitment and palmitoylation, while GlcNAcylation of 
a nearby serine does the same [50]. In the brain, zDHHC5 palmitoylation of d-catenin 
relies on its internalisation caused by synaptic activity-induced zDHHC5 
dephosphorylation [97]. Adapter protein interactions are promoted by palmitoylation of 
the zDHHC5 C tail [92, 93]. A common theme in the cellular regulation of zDHHC5 
therefore appears to involve post-translational modifications regulating substrate 
recruitment – with little evidence that the catalytic turnover of palmitate in the enzyme’s 
active site can be modified. Whether zDHHC5 recruitment and palmitoylation of NCX1 
is regulated in the same manner remains to be seen. However, the fact that changes 
in NCX1 palmitoylation induced by allosteric regulation require the presence of 
zDHHC5 is suggestive of cellular mechanisms regulating zDHHC5 recruitment and 
palmitoylation of NCX1 that remain to be discovered. 
The repertoire of substrates known to be palmitoylated by zDHHC5 therefore 
continues to expand. In epithelial cells zDHHC5 regulates cell adhesion via 
palmitoylation of desmoglein-2 and plakophilin-3 mediated by the adaptor protein 
Golga7b [93]. In multiple cell types a subtly different adaptor protein, Golga7, partners 
zDHHC5 in controlling non-apoptotic cell death [92]. Meanwhile in cardiac muscle 
zDHHC5 is emerging as a key regulator of intracellular Na via its ability to regulate two 
of the major cellular Na efflux routes, NCX1 and the Na pump via PLM [49, 50]. Given 
the central importance of intracellular Na for mitochondrial function [98-102], and the 
established defects in cellular sodium handling that underlie cardiac hypertrophy and 
heart failure [102-106], zDHHC5 regulation of cardiac Na handling is an area ripe for 
therapeutic exploitation. 
 
3.5. Palmitoylation dependent conformational changes within the intracellular loop of 
NCX1 favors XIP binding and ultimately regulates intracellular Ca2+ 
The NCX1 auto-inhibitory mechanism facilitated by its endogenous XIP domain has 
been always compelling to fully understand NCX1 pharmacology. Deciphering the 
molecular nature of XIP dependent auto-regulation of the exchanger could potentially 
pave the way to innovate pharmacological strategies to ameliorate inappropriate NCX1 
function in cardiac pathologies.  
The interaction of auto-inhibitory peptide with the XIP docking site, identified as the 
residues between 562 and 679 [107], enables NCX1 to inactivate. We had previously 
established that NCX1 must be palmitoylated in order to switch to the inactive state 
[13], and recently extended this observation to demonstrate that palmitoylation creates 
a space for XIP to bind NCX1 [22]. Disruption of NCX1 palmitoylation using 2-BP or by 
mutating the palmitoylated cysteine to alanine significantly decreased the relative 
amount of NCX1 affinity-purified by a biotinylated XIP peptide [22]. The region between 
NCX1 residues 562 and 679 defined as the XIP docking site includes part of CBD2 
and is considerably larger than XIP itself, which is only 25 amino acids. We 
hypothesised that the XIP binding site was considerably smaller. Employing peptide 
affinity purification and peptide array scanning approaches, we identified the precise 
binding site as residues 709-728, positioned close to NCX1 palmitoylation site. 
Deletion of amino acid residues between 709 and 728 did not change the 
palmitoylation status of NCX1, but led complete loss of XIP binding to NCX1 [22]. The 
implication of this finding is that the conformational changes within the intracellular loop 
of NCX1 initiated by palmitoylation create a binding site for the XIP domain just on the 
N terminal side of the palmitoylation site [22]. The insensitivity of non-palmitoylated 
NCX1 to inactivation, and reduced affinity purification of non-palmitoylated NCX1 by a 
biotinylated XIP peptide are both explained by this observation. 
So what of the previous observation that the XIP docking site lies in the region between 
residues 562 and 679 of NCX1 [107]? It is important to remember that XIP is not merely 
an NCX1-antagonist: the actions of XIP are to promote formation of an inactivated form 
of NCX1 that is incapable of transporting ions. In some respects this inactivated form 
is diametrically opposed to the activated state induced by calcium binding to the CBDs. 
XIP is therefore better regarded as an ‘inverse-agonist’, in which the actions of binding 
/ engagement and efficacy (inactivation) can be regarded as separate events. Our 
findings therefore imply that XIP binding is directly regulated by palmitoylation and 
requires residues 709-728, while XIP efficacy is indirectly regulated by palmitoylation 
(due to the effect on binding) and requires residues 562-679. There are important 
implications to this finding. Experimental strategies to antagonise the actions of XIP 
need only be targeted towards the XIP binding site. However, experimental or 
therapeutic strategies to enhance NCX1 inactivation may need to target both the XIP 
binding site as well as the region around CBD2 that is required for XIP efficacy. 
Antagonising XIP may therefore prove a much easier strategy than mimicking it. This 
will be the subject of future investigations. 
 
3.6. NCX1 palmitoylation and transmembrane Ca2+ flux 
Ultimately, by changing the sensitivity of NCX1 to inactivation by XIP, palmitoylation 
regulates transmembrane Ca2+ flux through NCX1 and hence intracellular Ca2+ levels. 
In cells engineered to express wild type NCX1, intracellular calcium is lower than in 
cells engineered to express unpalmitoylatable NCX1. Supporting this, increasing 
NCX1 palmitoylation in the cells by inhibiting its depalmitoylation with the APT1 
inhibitor PalmB reduced the intracellular calcium concentration in the cells expressing 
WT-NCX1 [22]. It is noteworthy that in HEK cells (resting membrane potential -24mV 
[108]), NCX1 acts as calcium influx pathway under physiological conditions (NCX1 
reversal potential -42mV). In excitable tissues with a resting membrane potential more 
negative than the reversal potential (-80mV, cardiac myocytes), NCX1 is 
predominantly a Ca2+ efflux pathway. Ultimately then, by changing the sensitivity of 
NCX1 to inactivation, the palmitoylation status of NCX1 has the potential to control 
intracellular calcium load in multiple cell types. For example, in cardiac muscle any 
reduction in NCX1 palmitoylation will reduce the the propensity of NCX1 to inactivate, 
enhance NCX1-mediated Ca2+ efflux, and reduce sarcoplasmic reticulum calcium 
content. As well as having a direct effect on contractility, enhanced NCX1-mediated 
Ca efflux is pro-arrhythmic (because it generates an inward current) and increases 
intracellular Na+, with all the negative impacts on mitochondrial function previously 
discussed.  
Putting all together, these results resolve an important question regarding what NCX1 
inactivation stands for in the cell. The fact that NCX1 palmitoylation status influences 
intracellular Ca2+ (despite NCX1-mediated currents under tightly controlled intracellular 
conditions being unchanged by palmitoylation [13, 14]) indicates that XIP-mediated 
‘tuning’ of NCX1 activity is an important factor even in the absence of external stimuli. 
Recent findings thus bring a thorough mechanistic insight into physiological relevance 
of XIP driven NCX1 inactivation at molecular level and its modulation by palmitoylation. 
 
4. Conclusion & Future Perspectives 
Recent findings highlighted here have brought a new dimension into the understanding 
of the role for palmitoylation in NCX1 function. NCX1 is dynamically palmitoylated at 
the cell surface by zDHHC5 and depalmitoylated by APT1. Palmitoylation is a key 
regulatory process for NCX1 inactivation and the control of intracellular calcium as well 
as for NCX1 interaction with lipid domains. However, the cellular events that control 
NCX1 palmitoylation and depalmitoylation as well as some aspects of the molecular 
nature of palmitoylation-complex still remain unclear. Indeed compared to post-
translational modifications such as phosphorylation, the palmitoylation field as a whole 
suffers from a relatively crude understanding of the upstream control of palmitoylating 
and depalmitoylating enzymes. The emerging evidence for palmitoylation cascades 
[50, 109], alongside an understanding of the importance of other post-translational 
modifications in the control of zDHHC-PAT activities and substrate interactions, holds 
promise for a clearer future. 
Turning to the role of NCX1 palmitoylation in the control of calcium handling in the 
heart. Much like phosphorylation, our understanding of the importance of this 
regulatory mechanism will be supported by transgenic models in which palmitoylating 
enzymes are knocked out and overexpressed, as well as in more subtle knockin 
models targeting individual palmitoylation sites. The importance of understanding any 
contribution of aberrant palmitoylation to cardiac pathologies cannot be overstated, 
and may open the door to therapeutic strategies that target substrate recruitment by 
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Figure 1: NCX1 schematic. The top panel shows full length NCX1, highlighting the 
positions of the transmembrane (TM) domains, and the large regulatory intracellular 
loop which includes the exchange inhibitory peptide (XIP), calcium binding domains 
(CBD) and palmitoylation site adjacent to the amphipathic a helix (a). The middle panel 
shows the sequence of the amphipathic helix, highlighting the enrichment of aromatic 
amino acids (Ø) in this structure. The bottom panel shows the small hydrophilic face 
of this helix in a helical wheel projection. 
 
  





































Figure 2: NCX1 behaviour in giant plasma membrane vesicles (GPMVs). A: 
Schematic of GPMV formation in the presence of vesiculation agents DTT or NEM. B: 
Schematic of a GPMV following phase separation into fluorescently labelled raft (red) 
and non-raft (green) phases. C: Increased colocalisation of raft and non-raft markers 
in the presence of WT versus C739A NCX1 suggests WT NCX1 impairs GPMV phase 
separation (Data adapted from Gök et al., 2020). D: Colocalisation of raft and non-raft 
markers with wild type and unpalmitoylatable NCX1 in phase-separated GPMVs. Left: 
increased raft colocalisation of WT versus C739A NCX1. Right: non-raft colocalisaton 
of wild type and C739A NCX1 (Data adapted from Gök et al., 2020). 
 
  
Figure 3: Illustration of NCX1 palmitoylation/ depalmitoylation cycle. NCX1 
palmitoylation is catalyzed by zDHHC5 (magenta color); a surface-membrane resident 
zDHHC-PAT, and reversed by APT1 (navy blue). Palmitoylation enables XIP 
engagement with its binding site, which is located close to the NCX1 palmitoylation 
site.  
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